Table 3.
Clinical and Pathological Characteristics of Blood Samples from Patients with Prostate Cancer
| Relapse status | None (n = 18) | Long PSADT (n = 35) | Short PSADT (n = 31) |
|---|---|---|---|
| Mean age (P = 0.268) | 58.33 | 59.43 | 56.77 |
| Cancer stage (P = 0.003893) | |||
| pT1 | 5 (6.0) | 1 (1.2) | 0 (0) |
| pT2 | 6 (7.1) | 12 (14.3) | 6 (7.1) |
| pT3a | 1 (1.2) | 10 (11.9) | 5 (6.0) |
| pT3b | 6 (7.1) | 12 (14.3) | 20 (23.8) |
| Gleason grade (P = 0.2248) | |||
| 6 | 5 (6.0) | 8 (9.5) | 3 (3.6) |
| 7 | 7 (8.3) | 21 (25.0) | 18 (21.4) |
| 8–10 | 6 (7.1) | 6 (7.1) | 10 (11.9) |
| Race (P = 0.08387) | |||
| Black | 0 | 1 | 0 |
| Unknown | 3 | 1 | 2 |
| White | 15 | 33 | 29 |
| Median follow-up (months) | 152 | 109.14 | 54.8 |
| Median time to progression (months) | NA | 47.27 | 3.23 |
| Median PSADT (months) | NA | 26 | 3.21 |
| Mean preoperative PSA (P = 0.868) | 10.48 | 12.17 | 10.87 |
Data are given as number (percentage) of the 84 samples unless otherwise indicated.
NA, not applicable.